A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of RC1416 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Latest Information Update: 21 Apr 2026
At a glance
- Drugs RC 1416 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Regenecore Biotech
Most Recent Events
- 17 Apr 2026 Status changed from not yet recruiting to recruiting.
- 18 Feb 2026 New trial record